A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
about
The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative StressDopamine depleters in the treatment of hyperkinetic movement disorders.Investigational agents for the management of Huntington's disease.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation
P2860
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@en
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@nl
type
label
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@en
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@nl
prefLabel
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@en
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@nl
P2093
P2860
P356
P1476
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
@en
P2093
Hong-Yan Qiu
Wei-Dong Le
Wen-Jie Xie
Xiao-Jie Zhang
P2860
P304
P356
10.1111/CNS.12425
P50
P577
2015-06-30T00:00:00Z